Therapeutic Plasma Exchange
Removes and replaces blood plasma to eliminate harmful autoantibodies, toxins, and pro-aging factors while refreshing the circulatory environment.
Evidence Summary
Therapeutic plasma exchange (TPE) is an established, well-characterized apheresis procedure with strong evidence for approved autoimmune and neurological indications (ASFA Category I), where large plasma-bound pathogenic factors are removed. Its use for cognitive and longevity outcomes is more recent and still emerging. In Alzheimer's disease, the randomized phase 2b/3 AMBAR trial (347 mild-to-moderate patients) found that TPE with albumin replacement slowed cognitive and functional decline versus sham exchange, and a 2025 real-world study (32 patients vs 194 matched historical controls) reported MMSE decline about 45% slower than controls. For general biological aging, a small 2025 single-blind randomized placebo-controlled trial in 42 healthy adults over 50 (Buck Institute) found that TPE — most notably TPE combined with IVIG — improved multiple epigenetic aging clocks versus placebo, though the study was small and short. Importantly, plasmapheresis without albumin or young-plasma replacement did not produce rejuvenation in a separate 2025 randomized trial and was associated with acceleration of some epigenetic clocks, underscoring that the replacement fluid and protocol matter. Overall, evidence for TPE as a longevity intervention is early and hypothesis-generating; it is not a proven anti-aging treatment and should be used for healthy-aging purposes only under qualified physician supervision.
Evidence Scale
Mechanism of Action
TPE mechanically separates plasma from blood cells using an apheresis device and replaces the removed plasma with 5% albumin (some protocols add IVIG, or use fresh frozen plasma). This clears large, plasma-bound molecules — autoantibodies, immune complexes, inflammatory cytokines, and circulating pro-aging factors — and, by diluting the plasma proteome, may reset age-related signaling in a manner conceptually related to the plasma-dilution effects seen in heterochronic parabiosis research. In the AMBAR program, TPE with albumin significantly lowered peripheral and central inflammatory mediators (for example IFN-gamma, eotaxin, MIP-1alpha, and ICAM-1). Fresh albumin also restores binding capacity for toxins, lipids, and hormones. The net effect is a transient refresh of the circulatory environment rather than a permanent change to cells.
Who Is This For?
Autoimmune conditions, neurological disorders, longevity optimization. Requires IV access.
Protocol & Dosing
Dose
Typically 1-1.5 plasma volumes per session.
Frequency
Weekly to bi-weekly
Duration
Varies by condition; 5-10 sessions common
Protocol Summary
Blood is drawn and passed through an apheresis device that separates plasma from cellular components; the removed plasma is replaced with 5% albumin (with or without IVIG in some protocols). Sessions typically process 1 to 1.5 plasma volumes over 1 to 3 hours. Alzheimer's trial protocols used an intensive phase of roughly six weekly sessions followed by monthly maintenance low-volume exchanges; longevity-oriented research protocols have used bi-weekly or monthly schedules. At Peak Human, TPE is delivered as a physician-supervised, biomarker-tracked service with individualized scheduling.
Latest Evidence
2024–2025: Alzheimer's trials, biological-age data, and important caveats
The strongest human evidence for TPE with albumin replacement is in Alzheimer's disease. The randomized phase 2b/3 AMBAR trial (347 mild-to-moderate patients) reported that PE-treated patients preserved memory, language, and processing speed versus sham, with improved quality of life. A 2025 real-world study in Argentina (32 patients vs 194 matched historical controls) supported this, finding MMSE decline about 45% slower than controls (p<0.001) and markedly better preservation of immediate (88% less deterioration) and delayed recall (74% less). Across 514 procedures, about 82% were uneventful and no severe adverse events were reported, with most side effects related to venipuncture.
For general biological aging, a 2025 single-blind randomized placebo-controlled trial in 42 healthy adults over 50 (Buck Institute, Aging Cell) found TPE improved multiple epigenetic aging clocks versus placebo, with bi-weekly TPE plus IVIG the most effective regimen; the procedure was well tolerated. Mechanistically, AMBAR analyses showed TPE lowered peripheral and central inflammatory mediators.
The picture is nuanced. A separate 2025 randomized trial found that plasmapheresis WITHOUT albumin or young-plasma replacement did not rejuvenate epigenetic clocks and was associated with acceleration of some of them — so the replacement fluid and protocol appear to matter a great deal. The longevity evidence remains early, small, and hypothesis-generating.
Educational information, not medical advice. TPE for healthy-aging is investigational and is used only under qualified physician supervision. Established, FDA-recognized TPE indications (autoimmune and neurological) are separate from the emerging longevity use described here.
References
AMBAR neuropsychological outcomes — Alzheimer's & Dementia (2021)Real-world TPE in Alzheimer's — J Alzheimer's Dis (2025)Multi-omics biological-age rejuvenation RCT — Aging Cell (2025)Plasmapheresis & biomarkers of aging (caveat) — Scientific Reports (2025)TPE & inflammatory mediators — Ann Clin Transl Neurol (2024)Latest Evidence · Human Data
Slower decline vs matched controls
Relative slowing of decline vs matched historical controls in a 2025 real-world study of 32 mild-to-moderate Alzheimer's patients (Taragano et al., J Alzheimer's Dis, 2025). Observational comparison against historical controls — supportive of, but not a substitute for, randomized data.
Interactions & Precautions
Contraindications
- Severe hypotension
- Citrate allergy
- Active bleeding
- Hemodynamic instability
Potential Risks
- •Infection
- •Bleeding
- •Allergic reaction to replacement fluids
Potential Side Effects
Practitioner Notes
Clinical annotations from Dr. Goel
Breakthrough longevity therapy based on parabiosis research. Simple plasma dilution with albumin may offer similar benefits at lower cost.
Dr. Sanjeev Goel
Chief Medical Officer, Peak Human
Available at Peak Human
TPE is offered as a physician-supervised, biomarker-tracked clinical service at Peak Human.
View the TPE serviceCost & Access
Cost Range
$$$$
Accessibility
Availability varies by location
Sample member
Longevity Operator
One number for your longevity journey.
FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.
- Metabolic
- Hormonal
- Cardiovascular
- Brain / Cognitive
- Sleep
- Musculoskeletal
- Gut
- Immunity / Inflammation